Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Each spray is structured to deliver 50MCG Dihexa, 50MCG Semax, and 50MCG Selank for controlled laboratory research models
Ohios February 2026 peptide compounding guidance added state-specific documentation mandates
162,163 Retatrutide (LY-3437943), a novel triple agonist developed by Eli Lilly that targets GLP-1R, GIPR and GCGR, has shown potential in preliminary clinical data for providing excellent blood sugar control and significant weight reduction
People who value an honest, provider-directed approach over unregulated products
Slight redness immediately after application fading within 15-30 minutes proves normal for some users, though persistent redness lasting hours suggests concentration reduction or product discontinuation
Schedule your appointment online or call us to reserve your spot
US$ 26.63
US$ 27.43
US$ 27.77
US$ 23.98
